JOHN R - Center for Adaptive Neural Systems - Arizona State ...

Denise Campagnolo, M.D. - Curriculum Vitae
Page 12 of 22
9. xxxxx Immunotherapy in Relapsing Remitting Multiple Sclerosis
Co-Investigator
10. A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy
and Safety of Betaseron® xxxx ug Subcutaneously Every Other Day with Avonex® xxxxx
ug Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients
Previously Treated with Avonex®
Co-Investigator
11. A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX® Compared with
AVONEX® in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or
Both in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Breakthrough
Disease on AVONEX® Monotherapy
Co-Investigator
12. A Randomized, Double-blind, Placebo-controlled, Parallel group, Dose-ranging Study to
Investigate the MRI Efficacy and the Safety of Three Months Administration of xxxxx
(xxxxx-xxxxx mg twice daily) in Subjects with Relapsing Multiple Sclerosis
Co-Investigator
13. Quality of Life/COST Study
Co-Investigator
14. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability
and Efficacy of xxxxx in Patients with Relapsing Multiple Sclerosis
Co-Investigator
15. Phase IV, multicenter, open label, randomized study of Rebif xxxxx mcg administered three
times per week by subcutaneous injection compared with Copaxone® xxxxx mg
administered daily by subcutaneous injection in the treatment of relapsing remitting multiple
sclerosis
Co-Investigator
16. MuSI-QoL Project: Field Study Design
Co-Investigator
17. A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy,
Tolerability and Safety of Copaxone® to that of High Dose Interferon (Betaseron® or
Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients
Co-Investigator
Revised 6/9/2008